BR112014004557A2 - compostos (tieno[2,3-b][1,5]benzoxazepin-4-il)piperazin-1-ila como agonistas inversos de h1/antagonistas de 5-ht2a de dupla atividade - Google Patents

compostos (tieno[2,3-b][1,5]benzoxazepin-4-il)piperazin-1-ila como agonistas inversos de h1/antagonistas de 5-ht2a de dupla atividade

Info

Publication number
BR112014004557A2
BR112014004557A2 BR112014004557A BR112014004557A BR112014004557A2 BR 112014004557 A2 BR112014004557 A2 BR 112014004557A2 BR 112014004557 A BR112014004557 A BR 112014004557A BR 112014004557 A BR112014004557 A BR 112014004557A BR 112014004557 A2 BR112014004557 A2 BR 112014004557A2
Authority
BR
Brazil
Prior art keywords
benzoxazepin
thieno
piperazin
activity
compounds
Prior art date
Application number
BR112014004557A
Other languages
English (en)
Inventor
James Ledgard Andrew
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112014004557A2 publication Critical patent/BR112014004557A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

resumo patente de invenção: "compostos (tieno[2,3-b][1,5]benzoxazepin-4-il)piperazin-1-ila como agonistas inversos de h1/antagonistas de 5-ht2a de dupla atividade". a presente invenção refere-se a um duplo agonista inverso de h1 /antagonista do receptor 5-ht2a da fórmula (i): , a seus usos e a métodos para prepará-lo.
BR112014004557A 2011-08-30 2012-08-22 compostos (tieno[2,3-b][1,5]benzoxazepin-4-il)piperazin-1-ila como agonistas inversos de h1/antagonistas de 5-ht2a de dupla atividade BR112014004557A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161528893P 2011-08-30 2011-08-30
PCT/US2012/051833 WO2013032804A1 (en) 2011-08-30 2012-08-22 (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS

Publications (1)

Publication Number Publication Date
BR112014004557A2 true BR112014004557A2 (pt) 2017-05-30

Family

ID=46829875

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014004557A BR112014004557A2 (pt) 2011-08-30 2012-08-22 compostos (tieno[2,3-b][1,5]benzoxazepin-4-il)piperazin-1-ila como agonistas inversos de h1/antagonistas de 5-ht2a de dupla atividade

Country Status (22)

Country Link
US (1) US9512140B2 (pt)
EP (1) EP2751115B1 (pt)
JP (1) JP6042436B2 (pt)
KR (1) KR101596607B1 (pt)
CN (1) CN103958523B (pt)
AU (1) AU2012300451B2 (pt)
BR (1) BR112014004557A2 (pt)
CA (1) CA2843514C (pt)
DK (1) DK2751115T3 (pt)
EA (1) EA024248B1 (pt)
ES (1) ES2650225T3 (pt)
HR (1) HRP20171824T1 (pt)
HU (1) HUE034845T2 (pt)
LT (1) LT2751115T (pt)
MX (1) MX350419B (pt)
NO (1) NO2776955T3 (pt)
PL (1) PL2751115T3 (pt)
PT (1) PT2751115T (pt)
RS (1) RS56537B1 (pt)
SI (1) SI2751115T1 (pt)
WO (1) WO2013032804A1 (pt)
ZA (1) ZA201400874B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2729474T (pt) * 2011-07-08 2018-06-05 Lilly Co Eli Compostos (tieno[2,3-b][1,5]benzoxazepin-4-il)piperazin-1-ilo tendo actividade dual como agonistas inversos de h1/antagonistas de 5-ht2a
EA026328B1 (ru) 2013-01-14 2017-03-31 Эли Лилли Энд Компани (ТИЕНО[2,3-b][1,5]БЕНЗОКСАЗЕПИН-4-ИЛ)ПИПЕРАЗИН-1-ИЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ АГЕНТОВ С ДВОЙНОЙ АКТИВНОСТЬЮ: ОБРАТНЫХ АГОНИСТОВ Н1/АНТАГОНИСТОВ 5-НТ
TW201625644A (zh) 2014-04-29 2016-07-16 美國禮來大藥廠 作為選擇性５－ＨＴＡ反向促效劑之（噻吩并［２，３－ｂ］［１，５］苯并氧氮呯－４－基）哌嗪－１－基化合物
WO2018177993A1 (de) 2017-03-31 2018-10-04 Bayer Cropscience Aktiengesellschaft Pyrazole zur bekämpfung von arthropoden
WO2018234488A1 (en) 2017-06-23 2018-12-27 Basf Se SUBSTITUTED CYCLOPROPYL DERIVATIVES
WO2019185413A1 (en) 2018-03-27 2019-10-03 Basf Se Pesticidal substituted cyclopropyl derivatives
KR20210106528A (ko) * 2018-12-21 2021-08-30 오게다 에스.에이. 3-메틸-1,2,4-티아디아졸-5-카보하이드라지드 또는 이의 메틸-d3 중수소화 형태의 합성
EP4043444A1 (en) 2021-02-11 2022-08-17 Basf Se Substituted isoxazoline derivatives
EP4291551A1 (en) 2021-02-11 2023-12-20 Basf Se Substituted isoxazoline derivatives
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7395251B2 (en) * 2005-07-01 2008-07-01 International Business Machines Corporation Neural networks for prediction and control
US7807828B2 (en) * 2005-08-11 2010-10-05 Hypnion, Inc. Olanzapine analogs and methods of use thereof

Also Published As

Publication number Publication date
NO2776955T3 (pt) 2018-06-02
HRP20171824T1 (hr) 2017-12-29
MX2014002473A (es) 2016-09-26
US20140171411A1 (en) 2014-06-19
ZA201400874B (en) 2015-10-28
US9512140B2 (en) 2016-12-06
MX350419B (es) 2017-09-05
HUE034845T2 (en) 2018-03-28
CA2843514A1 (en) 2013-03-07
AU2012300451B2 (en) 2016-10-13
KR20140051355A (ko) 2014-04-30
LT2751115T (lt) 2017-12-27
DK2751115T3 (en) 2017-10-23
ES2650225T3 (es) 2018-01-17
SI2751115T1 (sl) 2017-11-30
PT2751115T (pt) 2017-12-20
CN103958523B (zh) 2016-07-27
EP2751115B1 (en) 2017-09-20
WO2013032804A1 (en) 2013-03-07
EP2751115A1 (en) 2014-07-09
CA2843514C (en) 2017-01-10
CN103958523A (zh) 2014-07-30
PL2751115T3 (pl) 2018-02-28
RS56537B1 (sr) 2018-02-28
EA201490332A1 (ru) 2014-06-30
JP2014525440A (ja) 2014-09-29
JP6042436B2 (ja) 2016-12-14
AU2012300451A1 (en) 2014-01-30
EA024248B1 (ru) 2016-08-31
KR101596607B1 (ko) 2016-02-22

Similar Documents

Publication Publication Date Title
BR112014004557A2 (pt) compostos (tieno[2,3-b][1,5]benzoxazepin-4-il)piperazin-1-ila como agonistas inversos de h1/antagonistas de 5-ht2a de dupla atividade
CY1123365T1 (el) Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα
UA111640C2 (uk) ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
JO3494B1 (ar) مشتقات بنزوثيوفين وتركيبات منها كمواد انحلال لمستقبلات استروجين انتقائية
GEP201706774B (en) Heterocyclyl compounds
EA201401351A1 (ru) Производные бензимидазол-пролина
UA117122C2 (uk) Хінолонові похідні
CR20160043A (es) Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2 (1h)-ona que tienen actividad antagonista de receptores muscarínicos así como actividad agonista del receptor
BR112013002846A2 (pt) derivados de tandospirona deuterada como agonista do receptor de 5-ht1a
CR20140257A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2
EA201501163A1 (ru) Модуляторы рецептора cxcr7
HRP20180475T1 (hr) (TIENO[2,3-b][1,5]BENZOKSAZEPIN-4-IL)PIPERAZIN-1-ILNI SPOJEVI, DVOJNO AKTIVNI KAO INVERZNI AGONISTI H1/ANTAGONISTI 5-HT2A
ECSP13013016A (es) Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, y su uso como inhibidores de la cinasa del receptor vegf
BR112013025682A2 (pt) Compostos, composição farmacêutica, uso de um composto, combinação e dispositivo
CL2012002541A1 (es) Compuesto cristalino hidrato del hidrobromuro de agomelatina; metodo de preparacion del compuesto; composicion farmaceutica; uso del compuesto para tratar trastornos del sueño, estres, ansiedad, depresion mayor, esquizofrenia, entre otros.
BR112015015491A2 (pt) compostos (tieno[2,3-b][1,5] benzoxazepin-4-il) piperazin-1-ila com atividade dual como agonistas inversos h1/antagonistas 5-ht2a

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2633 DE 22-06-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.